期刊文献+

恶性淋巴瘤的生物治疗策略 被引量:6

Strategies of the Biological Therapy for Malignant Lymphoma
原文传递
导出
摘要 恶性淋巴瘤的发生率近年来呈逐年增长趋势,严重威胁着人类健康,传统手术和放化疗方法往往难以彻底治愈该病。随着生物技术的兴起和免疫学的快速发展,生物治疗策略已被越来越多地用于淋巴瘤的治疗。肿瘤疫苗、单克隆抗体和蛋白抑制剂的合理使用或与传统化疗药物联用可提高疗效,减少不良反应,提高淋巴瘤患者远期生存率。从免疫治疗和靶向治疗两方面介绍淋巴瘤生物治疗方法的研究近况。 In recent years, an increasing incidence of malignant lymphoma has become a serious threat to the human health. The patients with malignant lymphoma cannot be completely cured by traditional surgery, radiation therapy and chemotherapy. With a rapid development of biotechnology and immunology, biological treatment has been widely used in lymphoma treatment. Suitable applications of cancer vaccine, monoclonal antibodies and protein inhibitors, or their combination with the traditional chemotherapy drugs could enhance the effect of treatment, reduce the adverse reactions and increase the rate of long-term survival. The recent studies of biological therapies were discussed within the context of lymphoma immune therapy and targeted therapy.
出处 《药学进展》 CAS 2012年第5期207-215,共9页 Progress in Pharmaceutical Sciences
基金 国家基础科学人才培养基金(No.J0630858) 国家自然科学基金(No.30872393)
关键词 恶性淋巴瘤 生物治疗 免疫治疗 靶向治疗 肿瘤疫苗 单克隆抗体 malignant lymphoma biological therapy immune therapy targeted therapy tumor vaccine monoclonal antibody
  • 相关文献

参考文献5

二级参考文献79

  • 1颜次慧,梁中琴,顾振纶,秦正红.自噬在细胞生存和肿瘤发生中的作用[J].中国药理学通报,2005,21(3):269-273. 被引量:5
  • 2王荣福.肿瘤核素诊治现状与进展[J].同位素,2006,19(2):112-118. 被引量:17
  • 3Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma[ J]. Blood, 2005,105 : 1417-1423.
  • 4Zinzani PL, Pulsoni A, Perrotti A, et al. Fludarabine plus mitoxantmne with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follieular lymphoma[J]. J Clin Oneol, 2004, 22: 2654-2661.
  • 5Coiffier B, Haioun C, Ketterer N, et al. Rituximab ( anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase Ⅱ study [J]. Blood, 1998, 92: 1927-1932.
  • 6Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma [ J ]. N Engl J Med, 2002, 346 : 235-242.
  • 7Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Aduhe[ J]. J Clin Oncol, 2005, 23: 4117-4126.
  • 8Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large:B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MINT) Group[ J]. Lancet, 2006, 7: 379-391.
  • 9Abramson JS, Shipp MA. Advances in the biology and therapy of difuse large B-cell lymphoma: Moving toward a molecularly targeted approach[J]. Blood, 2005,106:1164-1174.
  • 10Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibr/tumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma[ J]. J Clin Oncol, 2002, 20: 2453- 2463.

共引文献22

同被引文献91

引证文献6

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部